Drug patent expiry isn’t a calendar event—it’s a portfolio risk model. Here’s how to forecast it by country.
If you manage a pharma portfolio, you already know the uncomfortable truth: patent expiry dates don’t just determine when exclusivity ends. The…

Generic entry is inevitable—unless you build a moat that can’t be copied.
For years, investors and operators have focused on the obvious battleground: composition-of-matter patents. But in the real world of branded drug economics, the most durable de…

Biotech IPOs can feel like a clean bet: a compelling pipeline, a credible management team, and a market hungry for the next breakthrough. But in life sciences, “breakthrough” doesn’t matter if the patent foundation is shaky—or if the clock is already r…

Biosimilar entry windows aren’t just math—they’re risk management. And the companies that treat them like a spreadsheet exercise keep paying for it.
In a recent piece from DrugPatentWatch, the focus is blunt: there are costly mistakes companies make wh…

Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the difference between a “go” and a “no-go” decision often comes down to one question: What does the patent landscape actually say, and what does it mean for…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Formulation Game
The patent “moat” around a blockbuster drug is rarely just one wall. It’s a layered fortress—primary composition claims, method-of-use claims, manufacturing proces…

Your pharmaceutical portfolio may have a time bomb in it—and patent expiration data is the fuse.
If you’re leading strategy, BD, or portfolio management, you already know the headline: patents expire, generics arrive, margins compress, and forecasts ge…

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a simple story: patents are destiny, litigation is inevitable, and “hard to challenge” is the same thing as “impossible to beat.”
But the real world is messier—and it’s getting more measurable.
In a recent piece from DrugPatentWatch, t…